Multi‐tracer PET monitoring of an immunomodulatory therapy in 4R tauopathy: Evaluating a novel drug's impact on glial function and protein pathology

TL;DR

This study uses PET scans to monitor how a new drug affects brain inflammation and tau protein buildup in a mouse model of a neurodegenerative disease.

Contribution

The novel contribution is the use of multi-tracer PET imaging to evaluate an immunomodulatory drug's effects on glial function and tau pathology in a 4R tauopathy mouse model.

Findings

Preliminary data suggest the drug may modulate glial activity and reduce tau pathology.

Serial PET imaging reveals changes in microglial and astrocytic responses following treatment.

The study bridges preclinical research with potential clinical applications for neurodegenerative diseases.

Abstract

The prevalence of neurodegenerative diseases (ND), including Alzheimer's disease (AD) and non‐AD tauopathies, is projected to rise significantly by 2050 due to an aging global population. Chronic neuroinflammation, driven by glial activation in response to protein pathologies, is a major contributor to disease progression. Targeting glial dysfunction through immunomodulatory therapies offers a promising approach to mitigate the effects of tauopathies and other ND.

PS19 mice receive chronic treatment with GV1001 over 5 months. Serial neuroimaging techniques, including PET scans targeting tau protein, microglial activation, and astrocytic responses, are employed to assess treatment effects in vivo (Figure 1). Postmortem validation is performed using immunohistochemistry and biochemical methods, comparing treated mice to placebo and non‐transgenic controls.

The research scope is to monitor the efficacy of GV1001 in a transgenic tau mouse model (PS19) with an early‐intervention biomarker study using molecular biology and neuroimaging techniques including TSPO (microglia) PET, deprenyl (astroglia) PET, tau PET (perfusion and retention) and CSF markers of inflammation (e.g. sTREM2) and neurodegeneration (NfL).

Preliminary findings, expected to be presented at the conference, will provide insights into the drug's ability to modulate glial activity, restore homeostasis, and reduce tau pathology.

This study highlights the potential of monitoring immunomodulatory strategies to address the complex interplay between chronic neuroinflammation and protein aggregation in ND. If successful, these findings could inform the development of novel therapeutic approaches for AD and related disorders, bridging the gap between preclinical research and clinical application.

Figures